Re: Debt

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Debt

in response to

Re: Debt

KayakerBC

posted on Apr 06, 2022 10:29AM

I'm betting on this one and it's not too far off.

https://clinicaltrials.gov/ct2/show/NCT04840589

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694:

Testing the Combination of ZEN003694 and Nivolumab (OPDIVO) With or Without Ipilimumab (YERVOY) in Solid Tumors, with 36 Participants with an estimated study completion date, Jan 1, 2023.

https://agoracom.com/ir/ZenithEpigenetics/forums/discussion/topics/774323-news-out-dosing-of-first-cancer-patient-with-a-combination-of-zen-3694-bristol-myers-squibb-s-immune-checkpoint-inhibitor-opdiv/messages/2348433#message